Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It
is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since it is …

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice …

Abstract Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase
inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has …